Terns Pharmaceuticals/$TERN

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Terns Pharmaceuticals

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Ticker

$TERN
Sector
Health Care
Primary listing
NASDAQ

Industry

Pharmaceuticals
Headquarters
Foster City, United States

Employees

59

ISIN

US8808811074
Website
www.ternspharma.com

TERN Metrics

BasicAdvanced
$377M
-
-$1.08
-0.17
-

What the Analysts think about TERN

Analyst ratings (Buy, Hold, Sell) for Terns Pharmaceuticals stock.

Bulls say / Bears say

Terns Pharmaceuticals' lead candidate, TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia, is progressing through Phase 1 clinical trials, potentially addressing a significant unmet medical need. (globenewswire.com)
Institutional investors have shown increased confidence in Terns Pharmaceuticals, with Barclays PLC boosting its holdings by 444.7% in the fourth quarter, indicating strong belief in the company's growth prospects. (marketbeat.com)
Analysts maintain a positive outlook, with Jefferies reiterating a 'Buy' rating and setting a price target of $22.00, suggesting significant upside potential from current levels. (markets.businessinsider.com)
Terns Pharmaceuticals reported a quarterly loss of $21.8 million for the quarter ended December 31, with no revenue, highlighting ongoing financial challenges. (tradingview.com)
The company's stock experienced a 43.0% decline in the same quarter, reflecting investor concerns over financial performance and market competitiveness. (tradingview.com)
Competition in the obesity treatment market is intensifying, with Eli Lilly's promising data on retatrutide potentially overshadowing Terns' offerings, posing a threat to market share. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

TERN Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TERN Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

TERN News

AllArticlesVideos
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

GlobeNewsWire·2 weeks ago
3 Penny Stocks Wall Street Sees With 243% Upside

3 Penny Stocks Wall Street Sees With 243% Upside

24/7 Wall Street·3 weeks ago
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TERN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs